Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Price Performance

Shares of NASDAQ AKTX opened at $2.31 on Monday. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $4.40. The business’s 50-day simple moving average is $2.73 and its 200-day simple moving average is $2.86.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.